SG10202002577XA - Cd3 binding polypeptides - Google Patents

Cd3 binding polypeptides

Info

Publication number
SG10202002577XA
SG10202002577XA SG10202002577XA SG10202002577XA SG10202002577XA SG 10202002577X A SG10202002577X A SG 10202002577XA SG 10202002577X A SG10202002577X A SG 10202002577XA SG 10202002577X A SG10202002577X A SG 10202002577XA SG 10202002577X A SG10202002577X A SG 10202002577XA
Authority
SG
Singapore
Prior art keywords
binding polypeptides
polypeptides
binding
Prior art date
Application number
SG10202002577XA
Other languages
English (en)
Inventor
Philip Tan
John W Blankenship
Original Assignee
Aptevo Res & Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptevo Res & Development Llc filed Critical Aptevo Res & Development Llc
Publication of SG10202002577XA publication Critical patent/SG10202002577XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10202002577XA 2015-09-21 2016-09-21 Cd3 binding polypeptides SG10202002577XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562221190P 2015-09-21 2015-09-21

Publications (1)

Publication Number Publication Date
SG10202002577XA true SG10202002577XA (en) 2020-04-29

Family

ID=58387225

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202002577XA SG10202002577XA (en) 2015-09-21 2016-09-21 Cd3 binding polypeptides

Country Status (19)

Country Link
US (1) US11352426B2 (ru)
EP (1) EP3352760A4 (ru)
JP (1) JP7002446B2 (ru)
KR (1) KR20180053322A (ru)
CN (1) CN108367004B (ru)
AU (1) AU2016326449A1 (ru)
BR (1) BR112018005573A2 (ru)
CA (1) CA2999138A1 (ru)
CO (1) CO2018004094A2 (ru)
EA (1) EA201890613A1 (ru)
HK (2) HK1251175A1 (ru)
IL (1) IL258202B2 (ru)
MX (1) MX2018003292A (ru)
MY (1) MY197562A (ru)
PH (1) PH12018500520A1 (ru)
SG (1) SG10202002577XA (ru)
UA (1) UA126278C2 (ru)
WO (1) WO2017053469A2 (ru)
ZA (1) ZA201802440B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069067A (ko) 2015-10-30 2018-06-22 엔비이-테라퓨틱스 아게 안티-ror1 항체
KR20180101554A (ko) 2016-01-20 2018-09-12 더 스크립스 리서치 인스티튜트 Ｒｏｒ１ 항체 조성물 및 관련 방법
SG10202102846SA (en) 2016-09-21 2021-04-29 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2019016381A1 (en) * 2017-07-20 2019-01-24 Nbe-Therapeutics Ag MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
EP3655439A1 (en) 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX2020001212A (es) 2017-08-07 2020-03-20 Nbe Therapeutics Ag Conjugados anticuerpo-farmaco a base de antraciclina que tienen alta tolerabilidad in vivo.
JP7387611B2 (ja) 2017-09-22 2023-11-28 ウーシー バイオロジクス アイルランド リミテッド 新規二重特異性ポリペプチド複合体
AU2018337142A1 (en) * 2017-09-22 2020-05-07 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CA3164385A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
US20230151102A1 (en) * 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
WO2022042488A1 (en) * 2020-08-24 2022-03-03 Epimab Biotherapeutics (Hk) Limited Anti-ror1 antibodies and related bispecific binding proteins
KR20230117379A (ko) 2020-12-01 2023-08-08 압테보 리서치 앤드 디벨롭먼트 엘엘씨 이종이량체 psma 및 cd3-결합 이중특이적 항체
AU2022276523A1 (en) 2021-05-21 2024-01-18 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
WO2023288191A1 (en) * 2021-07-13 2023-01-19 University Of Washington Multiple de novo designed protein binding proteins
WO2023061419A1 (en) * 2021-10-12 2023-04-20 Concept To Medicine Biotech Co., Ltd. Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
WO2023169419A1 (en) * 2022-03-09 2023-09-14 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-cd3 antibodies and uses thereof
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (486)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4782840A (en) 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US4935495A (en) 1984-12-21 1990-06-19 Oncogen Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas
US4906562A (en) 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5955315A (en) 1985-11-19 1999-09-21 Schering Corporation Nucleic acids encoding human interleukin-4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5897861A (en) 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
ATE152174T1 (de) 1989-09-20 1997-05-15 Abbott Lab Verfahren zur herstellung von fusionsproteinen
US6018031A (en) 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0512064B1 (en) 1990-01-23 1997-06-18 Tanox Biosystems, Inc. Extracellular segments of human ige immunoglobulin anchoring peptides and antibodies specific therefor
CA2077348A1 (en) 1990-03-02 1991-09-03 Stephen D. Gillies Antibody constructs with enhanced binding affinity
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US20030219446A1 (en) 1990-03-26 2003-11-27 Bristol-Myers Squibb Company Ligand for CD28 receptor on B cells and methods
GB9009106D0 (en) 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
EP0537293A4 (en) 1990-07-02 1993-09-08 Bristol-Myers Company Ligand for cd28 receptor on b cells and methods
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
JPH06506358A (ja) 1991-03-28 1994-07-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ ナチュラルキラー細胞に特異的なｄｎａおよびアミノ酸配列
JPH06508133A (ja) 1991-05-31 1994-09-14 ジェネンテク，インコーポレイテッド Ｈｉｖに関連した免疫性の血小板減少性紫斑病の治療
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
ATE170562T1 (de) 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69207603T2 (de) 1991-08-16 1996-09-12 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0586002B1 (en) 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
WO1994009034A1 (en) 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6482919B2 (en) 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5597707A (en) 1993-04-15 1997-01-28 Bristol-Myers Squibb Company Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5795572A (en) 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
JP2991499B2 (ja) 1993-09-02 1999-12-20 トラスティーズ・オブ・ダートマス・カレッジ 抗ｇｐ３９抗体およびその用途
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JPH09503759A (ja) 1993-09-22 1997-04-15 メディカル リサーチ カウンシル 抗体のリターゲッティング
GB9412166D0 (en) 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
DE69533544T2 (de) 1994-01-11 2006-02-23 Dyax Corp., Cambridge Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6380369B1 (en) 1994-01-27 2002-04-30 Human Genome Sciences, Inc. Human DNA mismatch repair proteins
JPH09509054A (ja) 1994-02-01 1997-09-16 アメリカ合衆国 抗体部分および非抗体部分を含む融合タンパク質
AU692239B2 (en) 1994-03-07 1998-06-04 Medarex, Inc. Bispecific molecules having clinical utilities
PT699237E (pt) 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
US5945273A (en) 1997-06-03 1999-08-31 Human Genome Sciences, Inc. Human oxalyl-coa decarboxylase
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
WO1996006941A1 (de) 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Gentherapie von erkrankungen, die durch das immunsystem bedingt sind, mit hilfe eines zellspezifischen zellzyklusregulierten wirkstoffes
US6380169B1 (en) 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5866330A (en) 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
WO1997013529A1 (en) 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
GB2310894A (en) 1996-03-06 1997-09-10 Clive William Efford Multi-engine drive unit
WO1997034633A1 (en) 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
EP1186300A1 (en) 1996-03-20 2002-03-13 Bristol-Myers Squibb Company Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DK0914155T3 (da) 1996-03-25 2006-06-26 Medarex Inc Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DE19613691A1 (de) 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
WO1998003670A1 (en) 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US5846948A (en) 1996-08-30 1998-12-08 Arch Development Corporation Herpes simplex virus ORF P is a repressor of viral protein synthesis
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
GB9618477D0 (en) 1996-09-04 1996-10-16 Univ Leeds Gene therapy
US5972361A (en) 1996-10-25 1999-10-26 The Procter & Gamble Company Cleansing products
DE19651443A1 (de) 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
EP0860445A1 (en) 1997-02-18 1998-08-26 Hoechst Aktiengesellschaft New nucleotide sequences for the cell cycle regulated expression of structural genes
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO1998040088A1 (en) 1997-03-11 1998-09-17 Les Laboratoires Aeterna Inc. Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
CA2284211A1 (en) 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6383746B1 (en) 1997-10-23 2002-05-07 The United States Of America As Represented By The Department Of Health And Human Services Functional promoter for CCR5
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
DK1049787T3 (da) 1998-01-23 2005-04-04 Vlaams Interuniv Inst Biotech Antistofderivater med flere anvendelsesmuligheder
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
EP1060194A1 (en) 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
AU3655899A (en) 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
EP1073721B1 (en) 1998-04-22 2005-08-31 Genvec, Inc. Efficient purification of adenovirus
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
AU760854B2 (en) 1998-06-22 2003-05-22 Immunomedics Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
ES2188202T3 (es) 1998-07-13 2003-06-16 Univ Texas Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
DE69911793T2 (de) 1998-07-28 2004-08-12 Micromet Ag Heterominikörper
DK1974747T3 (da) 1998-08-11 2012-09-17 Biogen Idec Inc Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
WO2000011149A1 (en) 1998-08-24 2000-03-02 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
WO2000027885A1 (fr) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
KR20010103655A (ko) 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
PT1131096E (pt) 1998-11-09 2010-04-14 Biogen Idec Inc Tratamento com anticorpo anti-cd20 de pacientes beneficiários de transplante de medula óssea ou transplante de células estaminais de sangue periférico
US6380371B1 (en) 1998-12-10 2002-04-30 The Regents Of The University Of California Endoglycan: a novel protein having selectin ligand and chemokine presentation activity
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
EP1035172A3 (en) 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US6383753B1 (en) 1999-03-31 2002-05-07 Regents Of The University Of Michigan Yeast mammalian regulators of cell proliferation
WO2000064954A1 (en) 1999-04-22 2000-11-02 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
DE60024436T2 (de) 1999-05-07 2006-08-17 Genentech, Inc., South San Francisco Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US7074403B1 (en) 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US6380382B1 (en) 1999-06-30 2002-04-30 Millennium Pharmaceuticals, Inc. Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
JP2003528805A (ja) 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
KR20020047098A (ko) 1999-07-29 2002-06-21 추후제출 ＨＥＲ2/ｎｅｕ에 대한 인간 모노클로날 항체
EP1210374B1 (en) 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
KR100816958B1 (ko) 1999-07-30 2008-03-26 메다렉스, 인코포레이티드 항-Ｆｃ 수용체 결합제를 포함하는 치료 화합물
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
IL149500A0 (en) 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP1257197A4 (en) 2000-02-25 2008-07-16 Health Research Inc METHOD FOR THE TRANSDERMAL SAMPLING OF ANALYTES
CA2404390A1 (en) 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
BR0109705A (pt) 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US6518277B1 (en) 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2405632A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
AU6138301A (en) 2000-05-08 2001-11-20 Medarex Inc Human monoclonal antibodies to dendritic cells
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
AU2001270134B2 (en) 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
CN1451043A (zh) 2000-06-29 2003-10-22 艾博特公司 双特异性抗体及其制备方法和用途
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
IL153764A0 (en) 2000-07-12 2003-07-06 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
IL152940A0 (en) 2000-07-19 2003-06-24 Orbotech Ltd Apparatus and method for electrical testing of electrical circuits
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
US20050054000A1 (en) 2000-08-11 2005-03-10 Stefan Dubel Fv constructs with an influenceable affinity for a substance that is to be linked
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
US7521054B2 (en) 2000-11-17 2009-04-21 The United States Of America As Represented By The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point
RU2179862C1 (ru) 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
IL157274A0 (en) 2001-02-12 2004-02-19 Medarex Inc Human monoclonal antibodies to fc alpha receptor (cd89)
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US20050118164A1 (en) 2001-03-09 2005-06-02 William Herman Targeted ligands
DE60239931D1 (de) 2001-04-02 2011-06-16 Genentech Inc Kombinationstherapie
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
MXPA03011365A (es) 2001-06-13 2005-03-07 Genmab As Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
EP1404366A4 (en) 2001-06-14 2006-06-07 Intermune Inc COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20030026780A1 (en) 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
EP1427829A4 (en) 2001-08-31 2005-10-12 Abmaxis Inc MULTIVALENT PROTEIN CONJUGATE WITH SEVERAL LIGANDEN BINDING RECORDORDOMAS
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
CA2461631A1 (en) 2001-09-28 2003-04-03 Elusys Therapeutics, Inc. Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
EP1439857B1 (en) 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
ES2283368T3 (es) 2001-11-14 2007-11-01 Affimed Therapeutics Ag Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos.
CN1189483C (zh) 2001-11-23 2005-02-16 上海中信国健药业有限公司 人源化抗cd3单克隆抗体
RU2004122702A (ru) 2001-12-26 2005-04-20 Иммуномедикс, Инк. (Us) Способы получения полиспецифичных, поливалентных средств из vh и vl доменов
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
KR20040077889A (ko) 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
JP4498746B2 (ja) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20030219436A1 (en) 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
CA2379586A1 (en) 2002-04-10 2003-10-10 William Herman Fluid targeted ligands
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
WO2003106622A2 (en) 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP4790413B2 (ja) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
SI1549344T1 (sl) 2002-10-10 2015-05-29 Merck Patent Gmbh FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
EP2298806A1 (en) 2002-10-16 2011-03-23 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/0722P and methods of use thereof
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
WO2004058171A2 (en) 2002-12-20 2004-07-15 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
WO2004058191A2 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN100402660C (zh) 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
CA2414148A1 (en) 2002-12-30 2004-06-30 William Herman Targeted ligands
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7811564B2 (en) 2003-01-28 2010-10-12 Proscan Rx Pharma Prostate cancer diagnosis and treatment
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
EP1599504B1 (en) 2003-02-25 2014-12-03 Vaccibody AS Modified antibody
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
CN1279056C (zh) 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
CA2529027C (en) 2003-06-13 2013-09-10 Immunomedics, Inc. D-amino acid peptides
EP1641826A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
ES2372495T3 (es) 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
ES2341252T3 (es) 2003-11-28 2010-06-17 Micromet Ag Composiciones que comprenden polipeptidos.
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005070966A2 (en) 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
SI1716178T1 (sl) 2004-02-16 2010-11-30 Micromet Ag Manj imunogene vezne molekule
JP4939397B2 (ja) 2004-03-30 2012-05-23 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ オブ エルサレム アレルギー性反応に関与する細胞を標的化するための二重特異性抗体、ならびにその組成物および使用
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CA2568661A1 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)
US20070237712A1 (en) 2004-06-14 2007-10-11 Rajasekaran Ayyappan K Methods of Redistributing Apical Target Antigens to Detect and Treat Cellular Proliferative Disease
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US8518403B2 (en) 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
MX2007000921A (es) 2004-07-22 2007-11-09 Univ Erasmus Medical Ct Moleculas de union.
MX2007001638A (es) 2004-08-11 2009-02-12 Trubion Pharmaceuticals Inc Proteinas de fusion del dominio de unión.
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US8066989B2 (en) 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
ATE525400T1 (de) 2004-12-01 2011-10-15 Trion Pharma Gmbh Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR100616666B1 (ko) 2005-01-27 2006-08-28 삼성전기주식회사 카본나노튜브에 구아니딘기를 형성하는 방법,구아니딘기가 형성된 카본나노튜브를 기판에 부착하는방법 및 이에 따라 제조된 카본나노튜브 및 기판
EP1851251A2 (en) 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
KR20070115967A (ko) 2005-02-18 2007-12-06 메다렉스, 인코포레이티드 전립선 특이 막 항원(ｐｓｍａ)에 대한 인간 모노클로날항체
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
US8034902B2 (en) 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
NI200800032A (es) 2005-07-25 2009-03-23 Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
CA2634387C (en) 2005-12-20 2015-11-24 Morphosys Ag Novel collection of hcdr3 regions and uses therefor
WO2007095338A2 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Functional antibodies
AU2007233831B2 (en) 2006-03-30 2013-02-14 Glaxo Group Limited Antibodies against amyloid-beta peptide
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP2009539841A (ja) 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
JP2010507394A (ja) 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP2094302A4 (en) 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008153636A1 (en) 2007-05-04 2008-12-18 Cellsignaling Technology, Inc. Phospho-specific antibodies to p13k regulatory subunit and uses thereof
MX2009012066A (es) 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
WO2008150485A2 (en) 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
CN101679456B (zh) 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
BRPI0814060A2 (pt) 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
AU2008282729B2 (en) 2007-08-01 2015-07-16 Scott & White Healthcare A fold-back diabody diphtheria toxin immunotoxin and methods of use
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2033657A1 (de) 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
US20100204222A1 (en) 2007-09-17 2010-08-12 GlaxoSmithKline, LLC Pyridopyrimidine derivatives as p13 kinase inhibitors
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
HUE025976T2 (en) 2007-09-27 2016-05-30 Fund Centro Nac De Investig Oncologicas Carlos Iii Imidazolothiadiazoles for use as protein kinase inhibitors
WO2009046294A2 (en) 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
DK2209786T3 (da) 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
AU2008312631A1 (en) 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
CN101835779B (zh) 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production
WO2009059030A1 (en) 2007-10-31 2009-05-07 Burnham Institute For Medical Research Pyrazole derivatives as kinase inhibitors
EP2220089A4 (en) 2007-11-13 2011-10-26 Icos Corp HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE-DELTA
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
WO2009070524A1 (en) 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
US8865699B2 (en) 2007-11-27 2014-10-21 Cellzome Ltd. Amino triazoles as PI3K inhibitors
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2132228T1 (sl) 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
US20110189093A1 (en) 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
AU2009266873A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
NZ590668A (en) 2008-07-02 2012-12-21 Emergent Product Dev Seattle TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS
WO2010014629A1 (en) 2008-07-28 2010-02-04 Trubion Pharmaceuticals, Inc. Multi-specific binding proteins targeting b cell disorders
DK2326350T3 (da) 2008-09-08 2013-12-16 Psma Dev Company L L C Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
EP2342231A1 (en) 2008-09-26 2011-07-13 Roche Glycart AG Bispecific anti-egfr/anti-igf-1r antibodies
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
KR101820535B1 (ko) 2008-10-01 2018-01-19 암젠 리서치 (뮌헨) 게엠베하 종간특이적 ｐｓｍａｘｃｄ3 이중특이적 단일쇄 항체
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
ES2657220T3 (es) 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20110217302A1 (en) 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
US20100135900A1 (en) 2008-11-13 2010-06-03 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
HUE062339T2 (hu) 2009-02-13 2023-10-28 Immunomedics Inc Sejten belül hasítható kötést tartalmazó immunkonjugátumok
CA2758751C (en) 2009-04-14 2017-03-21 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2683735A1 (en) 2011-03-10 2014-01-15 HCO Antibody, Inc. Bispecific three-chain antibody-like molecules
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
EP2525222A1 (en) 2011-05-17 2012-11-21 Markus M. Heiss Initial relative lymphocyte count as predictive biomarker
SG10201509588TA (en) * 2011-05-21 2015-12-30 Macrogenics Inc CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3
CN107586340B (zh) 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
PL2802607T3 (pl) 2012-01-13 2018-03-30 Julius-Maximilians-Universität Würzburg Dwuskładnikowa komplementacja funkcjonalna wywoływana przez podwójny antygen
WO2013121175A1 (en) 2012-02-16 2013-08-22 Ucl Business Plc Lysosome-cleavable linker
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
US20150031861A1 (en) 2012-03-09 2015-01-29 Ucl Business Plc Chemical Modification of Antibodies
CA2870545A1 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
RU2014145633A (ru) 2012-05-14 2016-07-10 Дженентек, Инк. Композиции и способы для диагностики и лечения опухолей
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
US20130309234A1 (en) 2012-05-18 2013-11-21 Trion Pharma Gmbh Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome
CN104363919A (zh) 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
CN104640562A (zh) 2012-07-13 2015-05-20 酵活有限公司 包含抗-cd3构建体的双特异性不对称异二聚体
CN109513003A (zh) 2012-08-14 2019-03-26 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
KR20140036905A (ko) 2012-09-18 2014-03-26 삼성전자주식회사 이중특이 항체를 포함하는 단백질 복합체
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2904016B1 (en) 2012-10-08 2018-11-14 Roche Glycart AG Fc-free antibodies comprising two fab-fragments and methods of use
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
JP2016503295A (ja) 2012-11-07 2016-02-04 ファイザー・インク 抗ｉｌ−１３受容体アルファ２抗体および抗体−薬物コンジュゲート
CN112079929A (zh) 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
DK2941302T3 (en) 2013-01-02 2018-10-08 Glenmark Pharmaceuticals Sa ANTIBODIES BINDING TO TL1A AND THEIR USES
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2014151438A1 (en) 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2016130819A2 (en) 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins

Also Published As

Publication number Publication date
JP2018531000A (ja) 2018-10-25
MY197562A (en) 2023-06-23
EA201890613A1 (ru) 2018-10-31
WO2017053469A3 (en) 2017-05-04
HK1251175A1 (zh) 2019-01-25
JP7002446B2 (ja) 2022-03-04
US11352426B2 (en) 2022-06-07
IL258202A (en) 2018-05-31
US20180273622A1 (en) 2018-09-27
UA126278C2 (uk) 2022-09-14
PH12018500520A1 (en) 2018-08-29
IL258202B2 (en) 2023-02-01
EP3352760A2 (en) 2018-08-01
ZA201802440B (en) 2023-05-31
HK1251480A1 (zh) 2019-02-01
IL258202B (en) 2022-10-01
CO2018004094A2 (es) 2018-07-10
EP3352760A4 (en) 2019-03-06
BR112018005573A2 (pt) 2019-01-22
WO2017053469A2 (en) 2017-03-30
CN108367004B (zh) 2022-09-13
KR20180053322A (ko) 2018-05-21
CA2999138A1 (en) 2017-03-30
CN108367004A (zh) 2018-08-03
MX2018003292A (es) 2018-08-01
AU2016326449A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
HK1251480A1 (zh) Cd3結合多肽
ZA202203250B (en) Cd3 binding antibodies
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL263840A (en) cd3 binding antibodies
IL255767A (en) New polypeptides
ZA201804317B (en) Altered april binding antibodies
EP3506964C0 (en) BINDING SYRINGE
HK1250040A1 (zh) 多肽
IL256298A (en) Multi-specific binding proteins
ZA201901862B (en) Modified factor h binding protein
IL269477A (en) Polypeptides that bind to IL-1R-1
IL266419A (en) Binding peptides
HRP20181700T1 (hr) Fascikl
ZA201707980B (en) Binding folder
GB201702069D0 (en) Binding polypeptides
GB201715149D0 (en) IL-ß binding antibody
GB201618186D0 (en) Binding members
GB201403306D0 (en) Binding Polypeptides
GB201515245D0 (en) Novel polypeptides
GB201413567D0 (en) Binding surfaces